SNMMI 2024
Clinical Needs Driving Radiopharmaceutical Research and Scalable Solutions
When: Sunday, June 9th | 6:30pm - 7:30pm
Where: Toronto Convention Center | South Building, 700 Level, Room 701B
Overview
This session will examine the well-established clinical utility of beta-emitting Lu-177 therapies and the potential of alpha-emitting Ac-225 and Auger-emitting
Tb-161, ongoing research to support the development of new radiopharmaceuticals, and how a sustainable supply of isotopes is being established to address the rapidly growing demands for clinicians and researchers.
Attendance is free to all attendees of the SNMMI Annual Meeting.
For more information or to register to attend SNMMI click here:
Watch the introduction below and register now to access the full program
Roger
Estafanos
Session Moderator
General Manager, ITM USA
Munir
Ghesani, MD
Expanding the use of theranostics & the clinical management of patients
Chief Medical Officer, UNITED THERANOSTICS
Danielle
Meyrick, PhD, MD
Growing Pipeline to Address Unmet Clinical Needs
Chief Medical Officer, ITM
Mark
Harfensteller, PhD
Scalable Solutions to Meet the Rapidly Growing Needs
Chief Operating Officer, ITM
Login
User login
Enter your username and password here in order to log in on the website